OVERVIEW

ABOUT US

StraxCorp technology grew out of research conducted at the University of Melbourne. StraxCorp addresses one of the major clinical and economic global healthcare challenges of today’s aging population – fragility fractures. Drugs today are safe and effective in preventing fragility fractures, but are underutilized through existing classifications, and as such bone fragility is underdiagnosed and undertreated. Two large studies recently published (2018) suggested that the majority of  fragility fractures may occur in the large population of non-osteoporotic patients.1,2.

StraxCorp is supporting a clinical solution, in conjunction with bone density testing, to deliver more clinical information to physicians to better assess overall fracture risk for all their patients. In addition, as the majority of fragility fracture costs are associated with patients over 70 years of age, StraxCorp has developed a specific diagnostic to detect imminent risk of fracture (within 1-2 years) for non-osteoporotic patients. When these non-osteoporotic patients are identified as ‘at risk’, patients may benefit from widely available safe and cost-effective therapies. The StraxCorp solution supports existing diagnostics with our global first and unique marriage of high-resolution peripheral quantitative CT scanning with Artificial Intelligence aided assessment of bone decay/fragility fracture risk. Strax HR-pQCT, with its rapid turnaround, can be run in imaging centers, hospitals or a doctor’s practice to enable better access to identifying bone fragility.

1. 7,254 patients – 89%, Samelson, Elizabeth J., et al. The Lancet Diabetes & Endocrinology 7.1 (2019): 34-43.

2. 14,613 patients – 79%, Trajanoska, Katerina, et al. Bone 114 (2018): 116-124.